Yannis Natsis leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Before joining EPHA in January 2016, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the UN and the private sector in Brussels and Athens. In May 2019, Yannis was appointed to the Management Board of the European Medicines Agency (EMA) by EU Member States. He is one of the two patient representatives on the Board with a 3-year mandate starting in June 2019. Since January 2018, he has also been a member of the Board of the European Health Forum Gastein (EHFG).

In this podcast, we discuss pricing and access to new medicines under the challenges of COVID-19, as well as balancing the potential impacts of compulsory licenses to address the pandemic with the need to maintain a viable EU investment market. We also touch on topics such as Europe's competitiveness in global biotech, the hospital exemption of oncology products such as CAR-T, the recent marked decline in authorisations of EU orphan products, and the recent NGO report on the Innovative Medicines Initiative.

Yannis is a founding member of the European Alliance for Responsible R&D and Affordable Medicines and represents the public health voice on the following groups: High Level Group (HLG) to the Round Table meetings for European Health Ministers and Heads of Europe of pharmaceutical companies; Health Technology Assessment (HTA) Network Stakeholder Pool of the European Commission.

Yannis Natsis leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Before joining EPHA in January 2016, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the UN and the private sector in Brussels and Athens. In May 2019, Yannis was appointed to the Management Board of the European Medicines Agency (EMA) by EU Member States. He is one of the two patient representatives on the Board with a 3-year mandate starting in June 2019. Since January 2018, he has also been a member of the Board of the European Health Forum Gastein (EHFG). In this podcast, we discuss pricing and access to new medicines under the challenges of COVID-19, as well as balancing the potential impacts of compulsory licenses to address the pandemic with the need to maintain a viable EU investment market. We also touch on topics such as Europe's competitiveness in global biotech, the hospital exemption of oncology products such as CAR-T, the recent marked decline in authorisations of EU orphan products, and the recent NGO report on the Innovative Medicines Initiative. Yannis is a founding member of the European Alliance for Responsible R&D and Affordable Medicines and represents the public health voice on the following groups: High Level Group (HLG) to the Round Table meetings for European Health Ministers and Heads of Europe of pharmaceutical companies; Health Technology Assessment (HTA) Network Stakeholder Pool of the European Commission.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Vital Health Podcast

Yannis Natsis leads the advocacy for better and a…